Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1999-06-03
2008-08-26
Parkin, Jeffrey S. (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S218100
Reexamination Certificate
active
07417136
ABSTRACT:
The invention encompasses nucleic acid molecules containing transcription units which encode the flavivirus M and E protein antigens. TheflavivirusesincludeJapanese encephalitis virus, dengue, yellow fever virusandSt. Louis encephalitis virus. The nucleic acids function to provide the M and E protein antigens when the nucleic acid resides in an appropriate host cell, especially when the host cell is the cell of a subject. The invention also encompasses a vaccine whose active agent is the nucleic acid. The invention further encompasses the cultured host cells when they contain within them nucleic acid molecules containing the transcription units. The invention in addition encompasses a method of immunizing a subject against flavivirus infection by administering to the subject an effective amount of a vaccine containing a nucleic acid molecule containing the transcription unit of the invention.
REFERENCES:
patent: 4810492 (1989-03-01), Fujita et al.
patent: 5021347 (1991-06-01), Yasui et al.
patent: 5229293 (1993-07-01), Matsuura et al.
patent: 5494671 (1996-02-01), Lai et al.
patent: 5514375 (1996-05-01), Paoletti et al.
patent: 6074865 (2000-06-01), Kelly et al.
patent: 6136561 (2000-10-01), Ivy et al.
patent: 6165477 (2000-12-01), Ivy et al.
patent: 6258788 (2001-07-01), Schmaljohn
patent: 6455509 (2002-09-01), Kochel et al.
patent: 53133627 (1978-11-01), None
patent: 63004895 (1988-01-01), None
patent: 63105682 (1988-05-01), None
patent: 89025725 (1989-05-01), None
patent: 65000611 (1990-01-01), None
patent: 67025408 (1992-01-01), None
patent: 7265093 (1995-10-01), None
patent: WO 90/01946 (1990-03-01), None
patent: WO 92/02548 (1992-02-01), None
patent: WO 92/03545 (1992-03-01), None
patent: WO 93/06214 (1993-04-01), None
patent: WO 98/37911 (1998-09-01), None
patent: WO 99/06068 (1999-02-01), None
patent: WO 99/63095 (1999-12-01), None
patent: WO 02/072036 (2002-09-01), None
Phillpotts, R. J., et al., 1996, Immunisation with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus, Arch. Virol. 141:743-749.
Kozak, M., 1987, At least six nucleotides preceding the AUG initiation condon enhance translation in mammalian cells, J. Mol. Biol. 196:947-950.
Konishi, E., et al., 1992, Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection, Virol. 188:714-720.
Aberle et al. “A DNA Immunization Model Study with Constructs Expressing the Tick-Borne Encephalitis Virus Envelope Protein E in Different Physical Forms”J Immunology163: 6756-6761, 1999.
Konishi et al. “Induction of Protective Immunity against Japanese Encephalitis in Mice by Immunization with a Plasmid Encoding Japanese Encephalitis Virus Premembrane and Envelope Genes”J Virology72(6): 4925-4930, Jun. 1998.
Lin et al. “DNA Immunization with Japanese Encephalitis Virus Nonstructural Protein NS1 Elicitis Protective Immunity in Mice”J Virology72(1): 191-200, Jan. 1998.
Ho et al. “DNA vaccination induces a long-term antibody response and protective immunity against pseudorabies virus in mice”Arch Virol143: 115-125, 1998.
Kochel et al. “Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice”Vaccine15(5): 547-552, 1997.
Wang et al. “Immune Response to Neonatal Genetic Immunization”Virology288: 278-284, 1997.
Phillpotts et al. “Immunization with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus”Arch Virol141: 743-749, 1996.
Venugopal et al. “Immunity to St. Louis encephalitis virus by sequential immunization with recombinant vaccinia and baculovirus derived PrM/E proteins”Vaccine13(11): 1000-1005, 1995.
Allison et al. “Synthesis and Secretion of Recombinant Tick-Borne Encephalitis Virus Protein E in Soluble and Particulate Form”J Virology69(9): 5816-5820, Sep. 1995.
Abstract, Japanese Patent Publication No. JP 5276941 “Non-infective structure particle preparation, useful as vaccine—by infecting preliminary flavivirus infected cell with cDNA integrated recombinant vaccinia virus, and then separating non-infective structure particles containing E protein of flavivirus” Oct. 26, 1993.
Wolff et al. “Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle” Hum Mol Genet 1(6): 363-369, Sep. 1992.
Konishi et al. “Mice Immunized with a Subviral Particle Containing the Japanese Encephalitis Virus prM/M and E Proteins Are Protected from Lethal JEV Infection”Virology188: 714-720, 1992.
Mason et al. “Japanese Encephalitis Virus-Vaccinia Recombinants Produce Particulate Forms of the Structural Membrane Proteins and Induce High Levels of Protection against Lethal JEV Infection”Virology180: 294-305, 1991.
Osatomi and Sumiyoshi “Complete Nucleotide Sequence of Dengue Type 3 Virus Genome RNA”Virology176: 643-647, 1990.
Seeger et al. “The cloned genome of ground squirrel hepatitis virus is infectious in the animal”Proc Natl Acad SciU.S.A 81(18): 5849-5852, Sep. 1984.
Alvarez et al. A Phase I Study of Recombinant Adenovirus Vector-Mediated Delivery of an Anti-erbB-2 Single-Chain (sFv) Antibody Gene for Previously Treated Ovarian and Extraovarian Cancer Patients.Hum. Gene Ther.8:229-242 (Jan. 20, 1997).
Selay. The Choice Carrier.Synthetic Vaccinesvol. I (edited by Arnon) CRC Press Inc., Boca Raton, FL. pp. 83-92 (1987).
Clarke et al. Techniques For Hemagglutination And Hemagglutination-Inhibition With Arthropod-Borne Viruses.Amer. J. Trop. Med. and Hyg.7:561-573 (1958).
Gruenberg et al. Partial Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Virus Type 2, New Guinea C and PUO-218 Strains.J. Gen. Virol.69:1391-1398 (1988).
Henchal et al. Dengue Virus-Specific And Flavivirus Group Determinants Identified With Monoclonal Antibodies By Indirect Immunofluorescence.Amer. J. Trop. Med. Hyg.31:830-836 (1982).
Hubálek et al. West Nile Fever-a Reemerging Mosquito-Borne Viral Disease in Europe.Emerg. Infect. Dis.5(5):643-650 (1999).
Kohler et al. Continuous cultures of fused cells secreting antibody of predefined specificity.Nature256:495-497 (Aug. 7, 1975).
Konishi et al. Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens.Vaccine12(7):633-638 (1994).
Kozak. Circumstances and Mechanisms of Inhibition of Translation by Secondary Structure in Eucaryotic mRNAs.Mol. Cell. Biol.9(11):5134-5142 (Nov. 1989).
Laemmli. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4.Nature277:680-685 (Aug. 15, 1970).
Lai et al. Immunization of Monkeys with Baculovirus Recombinant-expressed Dengue Envelope and NS1 Glycoproteins Induces Partial Resistance to Challenge with Homotypic Dengue Virus. InVaccines 90: Modern Approaches to New Vaccines including Prevention of AIDS, Cold Spring Harbor Laboratory, Cold Springs Harbor, NY pp. 119-124 (1990).
Mason et al. Sequence of the Dengue-1 Virus genome in the Region Encoding the Three Structural Proteins and the Major Nonstructural Protein NS1.Virology161:262-267 (1987).
Smithburn et al. A Neurotropic Virus Isolated From The Blood Of A Native Of Uganda.Am. J. Trop. Med. Hyg.20:471-492 (1940).
Tardei et al. Evaluation of Immunoglobulin M (IgM) and IgG Enzyme Immunoassays in Serologic Diagnosis of West Nile Virus Infection.J. Clin. Microbiol.38(6):2232-2239 (Jun. 2000).
Tsai et al. Japanese Encephalitis Vaccines. InVaccines(3rdedition) (edited by Plotkin and Orenstein), W.B. Saunders Co., Philadelphia, PA. Chapter 27, pp. 672-710 (1999).
Tsai et al. Japanese Encephalitis Vaccines. InVaccines(2nd edition) (edited by Plotkin and Mortimer), W.B. Saunders Co., Philadelphia, PA. Chapter 24, pp. 671-713 (1994).
Yang et al. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A.Nature382:319-324 (Jul. 25, 1996).
Anderso
Klarquist & Sparkman, LLP
Parkin Jeffrey S.
The United States of America as represented by the Secretary, De
LandOfFree
Nucleic acid vaccines for prevention of flavivirus infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid vaccines for prevention of flavivirus infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid vaccines for prevention of flavivirus infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4001534